Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.94 USD
Change Today -0.11 / -2.18%
Volume 785.3K
CERS On Other Exchanges
Symbol
Exchange
CERS is not on other exchanges.
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

cerus corp (CERS) Snapshot

Open
$5.08
Previous Close
$5.05
Day High
$5.08
Day Low
$4.86
52 Week High
01/5/15 - $7.03
52 Week Low
07/28/14 - $3.48
Market Cap
471.1M
Average Volume 10 Days
841.6K
EPS TTM
$-0.72
Shares Outstanding
95.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CERUS CORP (CERS)

cerus corp (CERS) Related Bloomberg News

View More Bloomberg News

cerus corp (CERS) Related Businessweek News

No Related Businessweek News Found

cerus corp (CERS) Details

Cerus Corporation operates as a biomedical products company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and designed to target and inactivate blood-borne pathogens, including viruses, bacteria, and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company’s INTERCEPT Blood System for platelets is designed to inactivate blood-borne pathogens in platelets donated for transfusion; INTERCEPT Blood System for plasma is designed to inactivate blood-borne pathogens in plasma donated for transfusion; and INTERCEPT Blood System for red blood cells is designed to inactivate blood-borne pathogens in red blood cells donated for transfusion. Cerus Corporation markets its platelet and plasma systems through its direct sales force and distributors. The company has collaboration with Baxter International, Inc. for the development and commercialization of the INTERCEPT Blood System. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

144 Employees
Last Reported Date: 03/16/15
Founded in 1991

cerus corp (CERS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $520.8K
Co-Founder, Chief Medical Officer, Chief Scie...
Total Annual Compensation: $426.5K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $308.4K
President of Cerus Europe and EEMEA
Total Annual Compensation: $281.6K
Senior Vice President of Regulatory Affairs, ...
Total Annual Compensation: $375.6K
Compensation as of Fiscal Year 2014.

cerus corp (CERS) Key Developments

Cerus Corporation Appoints Richard J. Benjamin as Chief Medical Officer, Effective July 13, 2015

Cerus Corporation announced that Richard J. Benjamin, MD PhD has been appointed as chief medical officer of the company, effective July 13, 2015. Dr. Benjamin joins Cerus from the American Red Cross where, as the chief medical officer, he oversaw the organization’s donor and patient safety issues related to blood collection and transfusion.

Cerus Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reaffirms Revenue Guidance for Core European and Middle East Markets for 2015

Cerus Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. Revenue for the first quarter of 2015 was $7.7 million, reflecting an increase in INTERCEPT disposable kit demand of 17% and a 2% decrease in reported revenue from $7.9 million reported in the first quarter of 2014. The difference between reported revenue and kit demand results from the weakness in the Euro. Because revenue for the first quarter of 2015 was driven exclusively by the European and Middle Eastern markets, reported revenue was negatively affected by an 18% weakening of the average Euro rates compared to the U.S. dollar, the company’s reporting currency. The first quarter results of 2015 also reflect the impact of weakness in the Russian market. Operating losses during the first quarter of 2015 were $14.4 million, compared to $9.2 million for the first quarter of 2014. Increased operating expenses incurred during the first quarter of 2015 relative to the same period in 2014 were the primary driver for the higher operating losses. Net loss before income taxes was $9.4 million against $0.2 million last year. Net loss for the first quarter of 2015 was $9.5 million, or $0.17 per diluted share, compared to net loss of $0.2 million, or $0.12 per diluted share, for the first quarter of 2014. Net losses were impacted by the operating losses and mark-to-market adjustments of the company's outstanding warrants to fair value, which resulted in non-cash gains of $6.3 million during the first quarter of 2015 compared to $9.0 million during the comparable period in 2014. Net losses were also impacted by foreign exchange losses of $1.1 million during the first quarter of 2015, compared to $0.02 million of foreign exchange gains during the first quarter of 2014. The company continues to expect annual revenue for 2015 for its core European and Middle East markets of $36 million to $38 million.

Cerus Corporation, Annual General Meeting, Jun 10, 2015

Cerus Corporation, Annual General Meeting, Jun 10, 2015., at 09:00 Pacific Standard Time. Location: 2550 Stanwell Drive. Agenda: To elect Daniel N. Swisher Jr., and Frank Witney, PhD as directors to the Board of Directors of the company to hold office until the 2018 AGM; to approve an amendment and restatement of 2008 equity incentive plan to increase the aggregate number of shares of common stock authorized for issuance there under by 5,000,000 shares and to make certain other changes thereto; to approve an amendment and restatement of 1996 employee stock purchase plan to increase the aggregate number of shares of common stock authorized for issuance there under by 1,500,000 shares; to approve, on an advisory basis, the compensation of the company's named executive officers; and to ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm for its fiscal year ending December 31, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CERS:US $4.94 USD -0.11

CERS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Grifols SA €36.27 EUR -0.58
View Industry Companies
 

Industry Analysis

CERS

Industry Average

Valuation CERS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.7x
Price/Book 4.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CERUS CORP, please visit www.cerus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.